iCARe is an acronym for Individualized Cellular Activity Reactor, a concept where immobilized cells will be probed for their reaction to a variety of substances - for example anti-cancer medicines, allergenic compounds, and toxins. The end goal is to develop this to such an extent that general physicians or quality control labs can quickly and easily test the effectiveness and/or safety of drugs, pollutants and any other materials up for question.

The iCARE concept was developed at the FAST conference during a 2-hour brainstorm session by young scientists challenged to create original research plans. Fleur van Beek was chosen to be the Principal Investigator of a group including Paula Borgonje (University of Groningen), André van den Doel (Radboud University), Alina Astefanei (University of Amsterdam), Milou Santbergen (Wageningen University), Gerjen Tinnevelt (Radboud University), and Nienke van Dongen (Wageningen University).

The team managed to convince both the industrial participants and the jury to invest in their iCARe idea. A prize of 5600 euros was awarded to the team to have a student carry out a feasibility study.